These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32675913)

  • 1. Ceftazidime/avibactam for specified infections.
    Aust Prescr; 2020 Jun; 43(3):98-99. PubMed ID: 32675913
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
    Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
    Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
    Das S; Li J; Riccobene T; Carrothers TJ; Newell P; Melnick D; Critchley IA; Stone GG; Nichols WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
    Mazuski JE; Gasink LB; Armstrong J; Broadhurst H; Stone GG; Rank D; Llorens L; Newell P; Pachl J
    Clin Infect Dis; 2016 Jun; 62(11):1380-1389. PubMed ID: 26962078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
    van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
    Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant
    Vena A; Giacobbe DR; Castaldo N; Cattelan A; Mussini C; Luzzati R; Rosa FG; Del Puente F; Mastroianni CM; Cascio A; Carbonara S; Capone A; Boni S; Sepulcri C; Meschiari M; Raumer F; Oliva A; Corcione S; Bassetti M
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32050434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
    De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
    Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying
    Castanheira M; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031200
    [No Abstract]   [Full Text] [Related]  

  • 14. In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
    Stone GG; Bradford PA; Newell P; Wardman A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials.
    Zhang Y; Tao LN; Qu XY; Niu JQ; Ding YH; Zhang SX
    Rev Assoc Med Bras (1992); 2018 Mar; 64(3):253-263. PubMed ID: 29641778
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
    Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
    J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.
    Tuon FF; Rocha JL; Formigoni-Pinto MR
    Infection; 2018 Apr; 46(2):165-181. PubMed ID: 29110143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.